Saroja Pharma In

Why is Saroja Pharma Industries India Ltd falling/rising?

As of 18-Jul, Saroja Pharma Industries India Ltd's stock price is at Rs 28.60, reflecting a decline of 4.51%. The stock has underperformed significantly over various periods, with a year-to-date decrease of 28.50%, and is trading close to its 52-week low while lagging behind the benchmark Sensex.

As of 18-Jul, Saroja Pharma Industries India Ltd's stock price is falling, currently at Rs 28.60, which reflects a decrease of Rs 1.35 or 4.51%. This decline is evident in the stock's performance over various periods, showing a significant drop of 8.77% over the past week and 11.73% over the past month, while the benchmark Sensex has shown positive returns during the same periods, gaining 0.53% and 1.03%, respectively. Year-to-date, the stock has decreased by 28.50%, compared to a smaller decline of 6.87% in the Sensex.<BR><BR>Additionally, the stock is trading close to its 52-week low, being only 2.1% away from that low point. It has underperformed its sector by 3.1% today and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Although there has been a rise in investor participation, with a 66.67% increase in delivery volume on July 14, this has not translated into a positive price movement. Overall, the combination of poor performance relative to the market and sector, along with the stock's position near its low, indicates the reasons for the current decline in Saroja Pharma Industries India Ltd's stock price.

Which are the latest news on Saroja Pharma In?

What does Saroja Pharma In do?

Saroja Pharma Industries India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, originally incorporated in 2019 and converted to a Public Limited Company in 2023. It has a market cap of INR 14 Cr, with key metrics including a P/E of 8.00 and a debt-equity ratio of 0.81.

Overview: <BR>Saroja Pharma Industries India Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated as a Private Limited entity on January 14, 2019, under the name "Saroja Pharma Industries India Private Limited." It later converted to a Public Limited Company, changing its name to "Saroja Pharma Industries India Limited" on April 18, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 14 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.81 <BR>Return on Equity: 9.37% <BR>Price to Book: 0.79 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Saroja Pharma In?

Saroja Pharma In's peers include Ortin Global, Beryl Drugs, Unjha Formul., Colinz Labs, Zenith Health, Ganga Pharma., Starsource Multi, and Vivanza Biosci. Saroja Pharma In has below-average management risk and growth ratings, with a 1-year return of -13.28%, significantly lower than Ortin Global's 62.42%.

Peers: The peers of Saroja Pharma In are Ortin Global, Beryl Drugs, Unjha Formul., Colinz Labs, Zenith Health, Ganga Pharma., Starsource Multi, and Vivanza Biosci.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ortin Global, Beryl Drugs, Colinz Labs, Zenith Health, Ganga Pharma., and Vivanza Biosci., while Average management risk is found at Saroja Pharma In and Unjha Formul. The Growth rating is Below Average for Ortin Global, Saroja Pharma In, Beryl Drugs, and the rest, while Unjha Formul. and Vivanza Biosci. show Average growth. In terms of Capital Structure, Good ratings are seen at Unjha Formul., Colinz Labs, and Zenith Health, while Saroja Pharma In, Ortin Global, Beryl Drugs, Ganga Pharma., Starsource Multi, and Vivanza Biosci. have Below Average ratings.<BR><BR>Return Snapshot: Ortin Global has the highest 1-year return at 62.42%, while Saroja Pharma In has a 1-year return of -13.28%, indicating a significantly lower performance compared to its peers. Additionally, Saroja Pharma In's six-month return is negative at -31.41%.

How has been the historical performance of Saroja Pharma In?

Saroja Pharma In's historical performance shows growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 53.73 Cr and profit after tax increasing to 1.03 Cr, despite significant increases in raw material costs and total liabilities. The company also improved its operating profit and earnings per share during this period.

Answer:<BR>The historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Saroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 Cr in Mar'24, alongside a rise in total liabilities to 39.55 Cr from 26.56 Cr. The company maintained a book value per share of 38.99 in Mar'25, up from 36.42 in Mar'24. Overall, while Saroja Pharma In experienced growth in sales and profits, it also faced rising costs and increased liabilities.

Is Saroja Pharma In overvalued or undervalued?

As of October 6, 2025, Saroja Pharma is considered overvalued with a PE ratio of 17.45 and has underperformed the Sensex with a return of -22.06%, making it a less attractive investment at its current price of 44.70.

As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation.<BR><BR>Given these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price of 44.70.

How big is Saroja Pharma In?

As of 23rd July, Saroja Pharma Industries India Ltd has a market capitalization of 14.00 Cr, classifying it as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 14.64 Cr and Total Assets of 26.56 Cr.

As of 23rd July, <BR><BR>Market Cap: Saroja Pharma Industries India Ltd has a market capitalization of 14.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 14.64 Cr and Total Assets totaling 26.56 Cr.

Who are the top shareholders of the Saroja Pharma In?

The top shareholder of Saroja Pharma In is Biju Gopinathan Nair, who holds 72.05% of the shares. The highest public shareholder is Swastika Investmart Ltd at 1.91%, with individual investors collectively owning 24.0%.

The top shareholders of Saroja Pharma In are primarily the promoters, with Biju Gopinathan Nair holding the largest stake at 72.05%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Swastika Investmart Ltd, which holds 1.91%. Additionally, individual investors collectively hold 24.0% of the shares.

What is the technical trend for Saroja Pharma In?

As of June 4, 2025, Saroja Pharma In has shifted to a bearish trend, supported by negative indicators from MACD, Bollinger Bands, and moving averages, despite a mildly bullish OBV on the weekly timeframe.

As of 4 June 2025, the technical trend for Saroja Pharma In has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish trend. Daily moving averages also indicate a bearish sentiment. The KST is bearish on the weekly timeframe, while the Dow Theory shows no trend in both weekly and monthly analyses. Although the OBV is mildly bullish on the weekly, it does not offset the overall bearish indicators. The stock has underperformed significantly compared to the Sensex over various time frames, further supporting the bearish outlook.

When is the next results date for Saroja Pharma In?

No Upcoming Board Meetings

Has Saroja Pharma In declared dividend?

No Dividend History Available